Somewhat Favorable News Coverage Somewhat Unlikely to Impact Horizon Therapeutics (HPTX) Stock Price

Press coverage about Horizon Therapeutics (NASDAQ:HPTX) has trended somewhat positive on Thursday, according to Accern Sentiment Analysis. The research firm identifies positive and negative news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Horizon Therapeutics earned a media sentiment score of 0.21 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 46.6791790500691 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Shares of Horizon Therapeutics (HPTX) opened at $45.99 on Thursday. The firm has a market cap of $964.29 and a price-to-earnings ratio of -1,533.00. Horizon Therapeutics has a one year low of $20.23 and a one year high of $46.96.

COPYRIGHT VIOLATION NOTICE: “Somewhat Favorable News Coverage Somewhat Unlikely to Impact Horizon Therapeutics (HPTX) Stock Price” was originally published by Markets Daily and is the sole property of of Markets Daily. If you are reading this story on another website, it was illegally stolen and reposted in violation of United States and international copyright law. The correct version of this story can be accessed at

About Horizon Therapeutics

Horizon Therapeutics, Inc, formerly Hyperion Therapeutics, Inc, is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat disorders in the areas of orphan diseases. The Company’s products include RAVICTI (glycerol phenylbutyrate) oral liquid, BUPHENYL and AMMONAPS (sodium phenylbutyrate) tablets and powder.

Insider Buying and Selling by Quarter for Horizon Therapeutics (NASDAQ:HPTX)

Receive News & Ratings for Horizon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply